Physicochemical, textural, volatile, and sensory profiles of traditional Sepet cheese

Autor: Ercan, D., Korel, F., Karagül Yüceer, Y., Kınık, Ö.

Publikováno v: In Journal of Dairy Science September 2011 94(9):4300-4312

An Assessment of the Penile Squamous Cell Carcinoma Surfaceome for Biomarker and Therapeutic Target Discovery.

Autor: Grass GD; Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Ercan D; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Obermayer AN; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Shaw T; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Stewart PA; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Chahoud J; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Dhillon J; Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Lopez A; Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Johnstone PAS; Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Rogatto SR; Department of Clinical Genetics, University Hospital of Southern Denmark-Vejle, Beriderbakken 4, 7100 Vejle, Denmark., Spiess PE; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Eschrich SA; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Publikováno v: Cancers [Cancers (Basel)] 2023 Jul 15; Vol. 15 (14). Date of Electronic Publication: 2023 Jul 15.

MST2 kinase suppresses rDNA transcription in response to DNA damage by phosphorylating nucleolar histone H2B

Autor: Pefani, D.E. Tognoli, M.L. Pirincci Ercan, D. Gorgoulis, V. O'Neill, E.

The heavily transcribed rDNA repeats that give rise to the ribosomal RNA are clustered in a unique chromatin structure, the nucleolus. Due to its highly repetitive nature and transcriptional activity, the nucleolus is considered a hotspot of genomic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::a13eb46d5fbea4a2fab7079f15e5559b
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2998056

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR -mutant lung cancer.

Autor: Eser PÖ; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.; Harvard Medical School, Boston, MA 02115, USA., Paranal RM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Son J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Ivanova E; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Kuang Y; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Haikala HM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., To C; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Okoro JJ; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Dholakia KH; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Choi J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Eum Y; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ogino A; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Missios P; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA., Ercan D; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Xu M; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Poitras MJ; Experimental Therapeutics Core, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Wang S; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ngo K; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Dills M; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Yanagita M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Lopez T; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Lin M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Tsai J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Floch N; Oncology R&D, Bioscience, AstraZeneca, CRUK Cambridge Institute, Robinson Way, Cambridge CB2 0RE, UK., Chambers ES; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Heng J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Anjum R; Bioscience, Oncology R&D, AstraZeneca, 25 Gatehouse Park, Waltham, MA 02451, USA., Santucci AD; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Michael K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Schuller AG; Bioscience, Oncology R&D, AstraZeneca, 25 Gatehouse Park, Waltham, MA 02451, USA., Cross D; Global Medical Affairs, Oncology Business Unit, AstraZeneca, 136 Hills Road, Cambridge CB2 8PA, UK., Smith PD; Oncology R&D, Bioscience, AstraZeneca, CRUK Cambridge Institute, Robinson Way, Cambridge CB2 0RE, UK., Oxnard GR; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Barbie DA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Sholl LM; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Bahcall M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Palakurthi S; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Gokhale PC; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Experimental Therapeutics Core, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Paweletz CP; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Daley GQ; Harvard Medical School, Boston, MA 02115, USA.; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA.; Harvard Stem Cell Institute, Cambridge, MA 02138, USA., Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Publikováno v: Science translational medicine [Sci Transl Med] 2021 Sep; Vol. 13 (609), pp. eabb3738. Date of Electronic Publication: 2021 Sep 01.

Budding yeast relies on G 1 cyclin specificity to couple cell cycle progression with morphogenetic development.

Autor: Pirincci Ercan D; Chromosome Segregation Laboratory, The Francis Crick Institute, London, UK., Chrétien F; Chromosome Segregation Laboratory, The Francis Crick Institute, London, UK., Chakravarty P; Bioinformatics and Biostatistics Science Technology Platform, The Francis Crick Institute, London, UK., Flynn HR; Proteomics Science Technology Platform, The Francis Crick Institute, London, UK., Snijders AP; Proteomics Science Technology Platform, The Francis Crick Institute, London, UK., Uhlmann F; Chromosome Segregation Laboratory, The Francis Crick Institute, London, UK. frank.uhlmann@crick.ac.uk.

Publikováno v: Science advances [Sci Adv] 2021 Jun 04; Vol. 7 (23). Date of Electronic Publication: 2021 Jun 04 (Print Publication: 2021).